http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Research from University of Washington Demonstrates High Performance of Abbott's SARS-CoV-2 Antibody Blood Test
-
Absolute Empowers Customers to Extend Power of Self-Healing to More Mission-Critical Security Applications
-
New Absolute Insights Reveal Increases in Enterprise and Education Device Usage, Vulnerability of Sensitive Data as Endpoints Remain Fragile Amid COVID-19 Outbreak
-
Absolute to Host Conference Call for Fiscal 2020 Third Quarter Financial Results
-
Absolute Declares Quarterly Dividend
-
Abbott Reports First-Quarter 2020 Results
-
Abbott (ABT) Launches Third COVID-19 Test, Laboratory-Based Antibody Blood Test
-
Abbott Launches Third COVID-19 Test, a Laboratory-Based Antibody Blood Test That Will Ship in the U.S. Starting Tomorrow
-
Abbott Announces Virtual Attendance at Annual Meeting of Shareholders
-
Abbott (ABT) Announces TriClip Becomes First Device of its Kind to Receive CE Mark for Minimally Invasive Tricuspid Valve Repair
-
Abbott's TriClip™ Becomes First Device of its Kind to Receive CE Mark for Minimally Invasive Tricuspid Valve Repair
-
Abbott (ABT) Announces FreeStyle Libre 14 Day System Now Available in U.S. for Hospitalized Patients with Diabetes
-
Abbott's FreeStyle® Libre 14 Day System Now Available in U.S. for Hospitalized Patients with Diabetes During COVID-19 Pandemic
-
Dorset & Wiltshire Fire and Rescue Service Rely on Absolute to Ensure Endpoint Resilience and Privacy of Sensitive Information
-
Abbott (ABT) Launches Molecular Point-of-Care Test to Detect Novel Coronavirus in as Little as Five Minutes
-
Abbott Launches Molecular Point-of-Care Test to Detect Novel Coronavirus in as Little as Five Minutes
-
Abbott Hosts Conference Call for First-Quarter Earnings
-
Abbott (ABT) Receives FDA Emergency Use Authorization for COVID-19 Test
-
Abbott Receives FDA Emergency Use Authorization and Launches Test to Detect Novel Coronavirus
-
Abbott Aims to Optimize TAVI Implants with European Approval of FlexNav™ Delivery System for the Company's Portico™ Valve
-
Abbott Declares 385th Consecutive Quarterly Dividend
-
New Real-World Data Show that Abbott's FreeStyle Libre System Delivers Positive Health Outcomes for People with Type 1 and Type 2 Diabetes
-
Abbott and Insulet Partner to Integrate Next-Generation Glucose Sensing and Automated Insulin Delivery Technologies for Seamless Diabetes Care
-
Abbott Introduces Next-Generation Heart Rhythm Management Devices in Europe, Featuring State-of-the-Art Patient App and Bluetooth Connectivity
-
Abbott (ABT) Granted FDA Breakthrough Device Designation for In-Development Fully Implantable Heart Pump System
-
Abbott's In-Development Fully Implantable Heart Pump System Earns FDA's Breakthrough Device Designation
-
Absolute Reports Fiscal 2020 Second Quarter Financial Results
-
Abbott (ABT) Announces First-of-Its-Kind Trial to Assess New Therapy Option for People at Risk of Stroke
-
Abbott Announces First-of-Its-Kind Trial to Assess New Therapy Option for People at Risk of Stroke
-
Abbott (ABT) Tendyne Device Receives World's First CE Mark for Transcatheter Mitral Valve Implantation
-
Abbott's Tendyne™ Device Receives World's First CE Mark for Transcatheter Mitral Valve Implantation
-
Abbott (ABT) Receives Expanded Indication From FDA for Directional Deep Brain Stimulation System to Treat Parkinson's Disease
-
Abbott Receives Expanded Indication From the U.S. FDA for Directional Deep Brain Stimulation System to Treat Parkinson's Disease
-
New Quality of Life and Functional Improvement Data From Abbott's BOLD and TRIUMPH Studies Reinforce Benefit of Proclaim™ XR Neurostimulation System In People Living with Chronic Pain
-
Abbott Reports Fourth-Quarter 2019 Results; Announces Strong Forecast for 2020
-
Absolute Declares Quarterly Dividend
-
Absolute Protects Patient Data and Supports HIPAA Compliance for Apria Healthcare
-
Abbott to Initiate Trial to Study MitraClip as an Option for Moderate Surgical Risk Patients
-
Abbott (ABT) Announces FDA Approves Less Invasive Surgical Approach for its Heart Pump to Help Patients Avoid Open Heart Surgery
-
FDA Approves Less Invasive Surgical Approach for Abbott's Heart Pump to Help Patients Avoid Open Heart Surgery
-
Abbott Hosts Conference Call for Fourth-Quarter Earnings
-
Abbott Raises Quarterly Dividend 12.5%, Increasing Payouts for 48 Straight Years
-
Abbott (ABT) Announces Robert B. Ford to Succeed Miles D. White as CEO on March 31
-
Abbott Announces Robert B. Ford to Succeed Miles D. White as Chief Executive Officer on March 31, 2020
-
Absolute Reports Fiscal 2020 First Quarter Financial Results
-
Abbott (ABT) Announces Discovery of New Strain of HIV
-
Abbott Announces Discovery of New Strain of HIV, Keeping Global Health Community a Step Ahead of the Virus
-
Klein Independent School District Maximizes One-to-One Program with Absolute Security and Analytics
-
The Australian Red Cross Blood Service Selects Abbott's Alinity s Solution for Blood and Plasma Screening
-
Abbott Reports Third-Quarter 2019 Results

